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Magnetically guided protein transduction by hybrid of nanogel 
chaperone with iron oxide nanoparticles 
Riku Kawasaki, Yoshihiro Sasaki*, Kiyofumi Katagiri, Sada-atsu Mukai, Shin-ichi Sawada and Kazunari 
Akiyoshi* 
Abstract: Protein pharmaceuticals show great therapeutic promise, 
but effective intracellular delivery remains challenging. To address 
the need for efficient protein transduction systems, we used a 
magnetic nanogel chaperone (MC): a hybrid of a polysaccharide 
nanogel, a protein carrier with molecular chaperone-like properties, 
and iron oxide nanoparticles, enabling magnetically guided delivery. 
The MC complexed with model proteins, such as BSA and insulin, 
and was not cytotoxic. Cargo proteins were delivered to the target 
HeLa cell cytosol using a magnetic field to promote movement of the 
protein complex toward the cells. Delivery was confirmed by 
fluorescence microscopy and flow cytometry. Delivered β-
galactosidase, inactive within the MC complex, became 
enzymatically active within cells, to convert a prodrug. Thus, cargo 
proteins were released from MC complexes via exchange 
interactions with cytosolic proteins. The MC is a promising tool for 
realizing the therapeutic potential of proteins. 
 Protein pharmaceuticals are promising for combating 
human diseases including cancer, metabolic disorders and 
autoimmune diseases.[1] More than 130 proteins or peptides 
have been approved for clinical use.[2] Compared with 
conventional small molecule drugs, protein pharmaceuticals 
have several advantages, derived from their specific and 
multiple functions and high biocompatibility.[1] Furthermore, 
therapy with proteins can avoid issues encountered with 
other types of agents, such as permanent or random 
genetic alterations of cells caused by nucleic acid drugs. 
Thus, protein pharmaceuticals, which have only temporary 
therapeutic effects, are often safer and more efficient 
alternatives than gene therapies.[1]  
 Despite their fascinating potential, protein 
pharmaceutical development remains challenging because 
of their physical and chemical instabilities, necessitating 
high doses. To date, many nanocarriers for protein 
pharmaceuticals have been designed and synthesized, 
including lipids,[3] polymers,[4] nanogels[5] and inorganic 
nanoparticles.[6] In addition, most protein pharmaceuticals 
(e.g., antigens, cytokines and transcription factors) exert 
their functions by binding to the cell membrane surface or to 
extracellular targets.[1] However, recent progress in 
molecular biology has indicated that intracellular delivery of 
proteins could increase their potential uses in cancer 
therapy or regenerative medicine.[2] Accordingly, effective 
systems for delivery of proteins into the cell, that is, protein 
transduction systems,[17] are needed to fully realize the 
therapeutic potential of proteins. 
 Recently, many nanocarriers with magnetic properties 
have been developed to achieve efficient intracellular drug 
delivery. For instance, magnetic nanoparticles coated with 
lipid,[8] polymers[9] and proteins[10] were designed as magnetically 
guided delivery systems. In particular, transfection methods 
using magnetic nanoparticles, known as magnetofection,[11] have 
been extensively investigated and their efficiencies confirmed in 
various cell lines. However, few examples have been described 
using covalent attachment of proteins to magnetic nanoparticles 
in magnetically guided protein delivery systems[12] because 
maintaining proteins in their innate and functional form would be 
difficult to achieve with such approaches.[13]  
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Figure 1. Design of a magnetically guided protein transduction system. a) 
Preparation of protein/MC complexes. [I] The MC was prepared by mixing a 
nanogel with hydrophobized iron oxide nanoparticles [II] Proteins were 
encapsulated within the polymer matrix of MC. b) Delivery of proteins by MC 
to the cytosol. [III] Movement of protein/MC complexes toward cells, guided 
by an external magnetic field. [IV] Release of proteins within the cell by 
exchange reactions of cargo proteins with cytosolic proteins. 
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To address these issues in protein transduction, two 
approaches were employed here. One was to develop 
techniques to handle proteins, inspired by molecular 
chaperones. The chaperone-like function is defined as one 
that traps proteins without causing their aggregation and 
releases them in native form. This is an important concept 
for the formulation of a protein pharmaceutical. The other 
approach employed here was efficient intracellular delivery 
using an external magnetic field, which is generally 
harmless to both recipient cells and cargo proteins. The 
basic idea for magnetically guided protein transduction is 
shown in Figure 1. Specifically, magnetically guided 
nanocarriers were designed and synthesized by hybridizing 
an amphiphilic polysaccharide nanogel with magnetic 
nanoparticles. The hybrid (magnetic nanogel chaperone, 
MC) was anticipated to have both the function of a nanogel 
as a protein nanocarrier and magnetic properties.  
We have developed physically crosslinked nanogels as 
protein nanocarriers.[14] For example, hydrophobic 
polysaccharides, such as cholesterol-bearing pullulan, form 
self-assembled nanogels in water via physical crosslinking 
by hydrophobic cholesterol groups.[15] One of the most 
attractive characteristics of the nanogels is their molecular 
chaperone-like function, enabling capture of proteins within 
their polymer matrix via hydrophobic interactions. In 
addition, the dynamic properties of self-assembled 
nanogels enable release of the proteins from the nanogel 
via exchange reactions with other proteins in the bulk 
phase.[14a] The “catch and release” chaperone function 
allowed nanogels to act as protein nanocarriers in the 
development of a cancer vaccine (in Phase 1 and 2 clinical 
trials), a nasal vaccine,[16] and delivery systems for 
cytokines such as interleukin-1[17] and bone morphogenetic 
protein.[18] We previously reported facile preparation of 
hybrids of nanogels and iron oxide nanoparticles with 
excellent theranostic properties including T2 relaxivity, for 
use as a magnetic resonance imaging (MRI) contrast agent, 
and a heat generator, for magnetic hyperthermia.[19] These 
preliminary results encouraged us to develop a nanocarrier 
to deliver protein pharmaceuticals into cells using an 
external magnetic field, which can induce movement of the 
nanocarrier toward targeted cells to deliver the cargo 
proteins within. 
 Preparation and detailed characterization of the hybrid 
were reported elsewhere.[18] Briefly, the hybrid was 
prepared by mixing an aqueous nanogel suspension 
formed with cholesterol-bearing pullulan (CHP) (100 µg 
mL−1) and an aliquot of hydrophobized iron oxide 
nanoparticles suspended in tetrahydrofuran19 (The 
hydrodynamic diameter of the magnetic nanoparticles was 
12 nm and their polydispersity index was 0.012).  
At first, to examine the appropriateness of the MC as an 
intracellular delivery carrier, viability of HeLa cells in the 
presence of the MC was evaluated using a modified MTT 
assay. Figure 2a shows the viability of cells treated with a 
pure CHP nanogel (100 µg mL−1) or a CHP nanogel (100 
µg mL−1) mixed with 1, 10 or 100 µg mL−1 iron oxide 
nanoparticles (MC1, 10, and 100, respectively, Figure S1, 
and Table S1). No apparent cytotoxicity was observed even 
at the highest concentration of iron oxide nanoparticles after 
irradiation of magnetic field for 24 h. This suggests that the 
MC could be used as non-toxic nanocarrier, even under 
magnetic field irradiation.  
Protein complexation with the MC was evaluated using 
fluorescently labeled bovine serum albumin (BSA, 68 kDa) 
as a model protein. BSA (17 µg mL−1) was incubated with 
MC (100 µg mL−1) for 24 h. Proteins incorporated with the 
MC were separated from free proteins in a magnetic field 
and the fluorescence intensity of the supernatant was 
measured to quantify the complexation ratio (%), expressed 
as the amount of incorporated protein relative to the total 
protein (Figure 2b). When BSA was mixed with MC1, all 
protein was incorporated into the nanogel within 3 h. In 
addition, the complexation rates depended on the ratio of 
nanogel to iron oxide nanoparticles, indicating that the 
protein binding capacity of the MC can be tuned by 
changing the incorporated concentration of iron oxide 
nanoparticles.  
 Dynamic light scattering analysis showed that the size of 
the MC1 increased from 100 to 180 nm after complexation 
with BSA (Figure 2c). However, the zeta-potential did not 
significantly change (from −1.0 to −0.4 mV), although MC 
Figure 2. Characterization of MC and its interactions with proteins. a) 
Cytotoxicity of MC in the absence (white) or presence (black) of a magnetic 
field. HeLa cells were treated with CHP nanogel or MC. The concentration of 
CHP nanogel was fixed at 100 µg mL
−1
. Three independent experiments were 
performed in triplicate. b) Complexation between MC (100 µg mL
−1
), open 
circle; MC1, open triangle; MC10, open square; MC100) and Alexa488-labeled 
BSA (17 µg mL
−1
), which were estimated by fluorescence spectroscopy after 
magnetic separation. Three independent experiments were performed in 
triplicate c) Size distribution of MC1 and MC1/BSA complexes. MC was 
dispersed in PBS (25 °C, pH 7.4). d) Transmission electron microscopic 
images of MC1/BSA complex (MC1, 100 µg mL
-1
; BSA: 17 µg mL
−1
) in PBS, 
scale bar indicates 50 nm.  
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interacted with anionic BSA under the pH conditions applied. 
These results indicate that BSA was encapsulated within 
the nanogel, shielding its anionic charge. Figure 2d shows 
representative morphological images of a MC/BSA complex 
observed by transmission electron microscopy, indicating 
that MCs maintained their spherical morphology after 
complexation with proteins.[17]  
Performance of MC as a magnetically guided 
intracellular protein nanocarrier was investigated by 
confocal laser scanning microscopy (CLSM). HeLa cells 
were exposed to a MC/BSA complex (100 µg mL−1; BSA: 
17 µg mL−1) for 24 h and magnetic fields (c.a. 0.5 T) were 
applied towards the cells from the bottom of the culture dish. 
The subcellular distributions of delivered carriers and 
fluorescence-labeled cargo proteins were observed by 
CLSM. Fluorescence from MC (red) and BSA (green) were 
detected in the cytosol when magnetically induced protein 
delivery was performed with MC1 (Figure 3a and S2c). In 
contrast, fluorescence was not detected in cells incubated 
with conventional nanogels, or with MC1 in the absence of 
a magnetic field (Figure S1). Flow cytometry also showed 
that proteins were effectively delivered by MC under a 
magnetic field (Figure 3b).  
The intracellular uptake efficiency of MC under the 
influence of a magnetic field depended on the strength and 
direction of the magnetic field toward the cells (Figure S3). 
The magnetically induced protein delivery systems with MC 
yielded, on average, a 100-fold enhancement of MC and 
BSA uptake compared with the same carrier in the absence 
of a magnetic field. The fluorescence from MC1 and cargo 
proteins dispersed separately in the cytosol after 24 h. In 
addition, the cellular uptake was not inhibited by incubation 
at 4 °C (Figure S4), suggesting that MCs were taken up by 
following two energy-independent pathways. One is direct 
crossing of the plasma membrane by spearing the lipid 
bilayer and the other is endocytosis-like uptake resulting 
from magnetic energy. To further examine the release of 
proteins from MCs, the co-localization of MC and BSA was 
estimated. As expected, the co-localization ratio was 
decreased from 80% at 4 h to 30% at 24 h. These results 
indicate that the proteins were released from MC within 
cells after 24 h, because of an exchange reaction between 
cargo and cytosolic proteins.  
To demonstrate protein release from MC, MC/BSA 
complex (MC1, 100 µg mL−1; BSA, 17 µg mL−1) was co-
incubated with highly concentrated serum proteins. Release 
of incorporated proteins was quantified after magnetic 
separation of complexed protein to free protein. As shown 
in Figure 3c, BSA was not released from MC in PBS, 
whereas BSA was gradually released from MC in the 
presence of concentrated serum proteins in fetal bovine 
serum (FBS). The protein release efficiency was 
accelerated by increasing the concentration of serum 
proteins with FBS (10% FBS to 20% FBS). The serum 
proteins were detected in MC after mixing with FBS and 
incubation for 24 h by polyacrylamide gel electrophoresis 
(SDS-PAGE, Figure S5). These results indicate that the 
cargo proteins were replaced with serum proteins via an 
exchange reaction. Generally, the cytosol is filled with 
highly concentrated proteins. Accordingly, MC released 
cargo proteins within the cytosol through a protein 
exchange reaction. Similar protein release was observed 
with insulin as a lower molecular weight model protein 
(Figure S6). 
 The function of proteins delivered by MC to the cytosol 
was investigated with a hydrolytic enzyme, β-galactosidase 
(β-gal). When a solution of β-gal (0.42 µg mL−1) and MC 
(100 µg mL−1) was incubated for 24 h, 52% of β-gal was 
complexed with MC. The MC/β-gal complex was then 
separated from free β-gal and its enzymatic activity 
evaluated by monitoring the hydrolysis of the galactosyl 
moiety of non-fluorescent Tokyo-green β-gal (10 nM) to 
fluorescent Tokyo-green. As shown in Figure 4a, β-gal was 
inactivated by complexation with MC. After addition of FBS 
to the complex, however, β-gal recovered its enzymatic 
activity, probably because of its release and refolding via 
protein exchange reactions with serum proteins in FBS. 
These results showed that MC acted as an artificial 
molecular chaperone, enabling it to catch and release cargo 
proteins via exchange reactions with cytosolic proteins.  
Protein transduction efficiencies were directly evaluated 
by monitoring enzymatic activity of MC-delivered β-gal 
within Hela cells. The complex of β-gal with MC was 
incubated with Hela cells for 24 h under a magnetic field 
Figure 3. Cell uptake of MC/Alexa488-BSA complexes under irradiation in a 
magnetic field. a) Confocal laser scanning microscopic images of HeLa cells 
after incubation for 24 h with a complex of rhodamine B-labeled MC1 with 
Alexa488-labeled BSA under a magnetic field (MC1, 100 µg mL
−1
; BSA, 17 
µg mL
−1
). The scale bar indicates 20 µm. b) Mean fluorescence of rhodamine 
B-labeled MC1 (red) or Alexa488-labeled BSA (green) accumulated in HeLa 
cells, as determined by flow cytometry after 24 h incubation with nanogel/BSA 
complexes, or MC1/BSA complexes. c) Protein release in FBS, mimicking the 
intracellular environment. After complexation with BSA, PBS (○) or FBS 
(10%◇, 20%△) were added to the complex and labeled protein release was 
determined by fluorescence spectroscopy after magnetic separation. Three 
independent experiments were performed in triplicate. 
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and then CLSM observation was carried out. No 
fluorescence was detected in the case of free β-gal, the 
nanogel/β-gal complex, and the MC/β-gal complex without 
a magnetic field (Figure S7). However, when β-gal was 
delivered within HeLa cells using MC under a magnetic field, 
the fluorescence from Tokyo green, which was generated 
by the hydrolysis of Tokyo-green β-gal, was clearly 
observed throughout the cytosol (Figure S7d or f). In 
contrast, lower fluorescence emission from Tokyo green 
was observed when β-gal was delivered from a cationic 
nanogel as a positive control. 
The enzymatic activity was also quantified by flow 
cytometry. Fluorescence intensity from cells treated with a 
MC1/β-gal complex under a magnetic field was 100 times 
higher than without a magnetic field (Figure 4b). The 
enzymatic activity within cells gradually decreased, over 72 
h, to 8.5% (Figure S8). The disappearance of protein 
activity within cells is advantageous for protein therapies 
that require temporal pharmaceutical effects.  
 A prodrug assay was conducted using β-gal conjugated 
with cytotoxic 5-fluorouridine (5-fluorouridine-5′-O-β-
galactopyranoside, 5-FUR-β-gal) as a model prodrug 
substrate. When the galactosyl moiety of 5-FUR-β-gal was 
hydrolyzed by β-gal, the product 5-FUR showed dose-
dependent cytotoxicity, whereas 5-FUR-β-gal was not 
cytotoxic (Figure S9). After magnetically guided protein 
transduction using MC, an apparent cytotoxicity from 5-FUR 
for Hela cells was observed (Figure 4c). Thus, the delivered 
β-gal showed enzymatic activity within cells to convert non-
cytotoxic 5-FUR-β-gal into cytotoxic 5-FUR.  
 Finally, the utility of MC for DDS was assessed by 
delivering caspase 3, which is a known cytosolic protease 
that participates in a signaling pathway leading to 
programed cellular death (apoptosis). The caspase 3 or 
MC/caspase 3 complex was incubated with murine colon 
cancer cells (CT26 cells) for 24 hr. An apparent cytotoxicity 
was observed only when caspase 3 was delivered by MCs 
under the influence of a magnetic field (Figure 4d). In 
addition, it was proven using flow cytometry that cell 
destruction was induced through an apoptosis pathway by 
the delivered caspase 3 (Figure S10). 
 In conclusion, we demonstrated a facile magnetically 
guided protein transduction method using polysaccharide 
nanogels with iron oxide nanoparticles. The chaperone-like 
function of nanogels and the magnetic properties of iron 
oxide enabled highly efficiency delivery of proteins in their 
active forms to target cells. Consequently, our strategy has 
great potential as a key technique for protein transduction. 
We believe that supramolecular chemistry-based 
approaches such as ours have unique features applicable 
to delivering a wide range of proteins for protein-based 
therapies or regenerative medicine in the near future.  
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1. Materials and methods 
 
Materials. Cholesterol-bearing pullulan (CHP), in which the pullulan (Mw, 1.0×105 g mol−1) was 
substituted with 1.3 cholesteryl ester groups per 100 glucose units, was a gift from Nippon Oil and Fat 
Corporation (Tokyo, Japan). Alexa fluor 488-labeled bovine serum albumin (Alexa488-BSA, 68 kDa), 
Fluorescein isothiocyanate-labeled insulin (FITC-insulin, 28 kDa) and β-galactosidase from Escherichia 
coli. (β-gal, 168 kDa) were from Sigma-Aldrich (St. Louis, MO, USA). TokyoGreen-β-Gal, 
5-fluorouridine (5-FUR), and 5-fluorouridine-5′-O-β-D-galactopyranoside (5-FUR-β-gal) were from 
Sekisui Medical (Tokyo, Japan), TCI (Tokyo, Japan) and Funakoshi (Tokyo, Japan), respectively. A 
Cell-Counting Kit-8 (CCK-8) was obtained from Dojindo Laboratories (Kumamoto, Japan). 
 
Synthesis of rhodamine B-labeled CHP. Rhodamine B-labeled CHP (degree of substitution of the 
rhodamine B moiety per 100 glucose units of 0.2) was synthesized as previously described [1]. Briefly, 
CHP was vacuum-dried at 70 °C for 3 d. CHP, di-n-butytin dilaurate (DBTDL; Sigma Aldrich) and 
rhodamine B isothiocyanate (RITC; Sigma Aldrich) were dissolved in anhydrous dimethyl sulfoxide 
(DMSO). The concentrations of CHP, DBTDL, and RITC were 10 mg mL−1, 20 and 2.0 mM, 
respectively. The resulting solution was precipitated twice into a mixture of diethyl ether and ethanol 
(8:2, v/v). The isolated solid material was vacuum-dried at room temperature overnight and suspended 
in DMSO (CHP concentration, 10 mg mL−1). The suspension was dialyzed against DMSO and water. 
The degree of substitution of the rhodamine B to the glucose units of the pullulan was estimated using 
UV-vis spectroscopy (JASCO, Tokyo, Japan) at 558 nm.  
 
Preparation of nanogel with iron oxide nanoparticles (MC). MC was prepared as previously 
described [2]. Briefly, CHP was suspended in Milli-Q water, and stirred overnight at room temperature. 
The solution was sonicated using a probe-type sonicator (Sonifier 250, Branson, Danbury, USA) at 40 
W for 15 min with cooling on ice. The solution was filtered through 0.22 µm polyvinylidene difluoride 
filters (Millex-HV, Millipore, Bedford, MA, USA). Oleic acid coated Fe3O4 nanoparticles were 
synthesized via a conventional hydrothermal process and were purified by removing byproducts in 
n-hexane, with centrifugation. The Fe3O4 nanoparticles were then re-dispersed in THF (0.2, 2.0, 20 mg 
mL−1). MC was obtained by injecting the THF suspension of the oleic acid-coated Fe3O4 nanoparticles 
into a CHP nanogel aqueous suspension with vortex mixing. The solution was lyophilized to remove 
THF and re-dispersed in PBS. 
 
Basic characterization of MCs. The number of iron oxide nanoparticles incorporated into a nanogel 
was quantified by counting the number of iron oxide nanoparticles obtained in TEM images of MC 1, 
10 or 100, respectively. (N=50)  
 
Cytotoxicity of MC. HeLa cells were seeded on a 96-well plate (BD Falcon, New Jersey, USA) at a 
density of 5.0×103 cells/well and cultured overnight. After medium was exchanged with fresh 
Dulbecco’s modified Eagle’s medium (DMEM), the MC suspension was added to each well. After 
incubation for 24 h, a Cell Counting Kit-8 reagent (10 µL) was added to each well and plates were 
further incubated for 2 h. Absorbance at 450 nm was measured with a plate reader. Cell viability was 
calculated relative to that for untreated cells. This assay employed a modified MTT dye reduction assay 
using WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt) (Cell Counting Kit-8, Dojindo Laboratories), according to the manufacturer’s 
instructions. 
 
Complexation of proteins with MC. Protein complexation was confirmed after magnetic separation of 
the complex from free protein. MC and proteins (FITC-insulin, Alexa488-BSA, or β-galactosidase) 
were mixed and incubated for 24 h at 40 °C. The concentrations of MC, FITC-insulin, Alexa488-BSA 
and β-galactosidase were 100, 14, 17 and 0.42 µg mL−1, respectively. At each timepoint, proteins 
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incorporated into MC were magnetically separated from free proteins, and the complexation ratio was 
determined according to the following equation: 
 
Complexation ratio (%) = ( 1 − f / f0 ) ×100     
 
where f and f0 are the fluorescence intensity from released proteins and whole proteins, respectively. 
This was assessed by measuring either fluorescence intensity in a fluorescence spectrometer (FP-6500, 
JASCO, Japan, Tokyo) or absorbance at 280 nm in a UV-vis spectrophotometer. 
 
Characterization of MC/protein complexes. Dynamic light scattering and zeta-potential 
measurements were performed with a Zetasizer Nano instrument (Malvern Instruments, Worcestershire, 
U.K.) operating at a wavelength of 632.8 nm and a 173° detection angle. The hydrodynamic diameter of 
the MC or MC/protein complex (CHP concentration: 100 µg mL−1) was determined with a Laplace 
inversion program. The zeta-potential measurements were performed using a capillary zeta-potential 
cell. The morphology of the MC/protein complex was evaluated by transmission electron microscopy 
(TEM) (HT-7700, Hitachi, Tokyo, Japan). TEM was performed at an acceleration voltage of 100 kV 
and a beam current of 20 µA. The specimens were prepared by dropping 10 µL of a MC/protein 
complex suspension on a grid. 
 
Cellular uptake of proteins. HeLa cells were seeded on a 12 mm glass-bottomed dish (Iwaki, Osaka, 
Japan), at a density of 1.0×105 cells per dish, and incubated overnight. After the medium was exchanged 
with fresh DMEM, MC/protein complex was added to each dish. The final concentrations of MC, 
insulin and BSA were 100, 14 and 17 µg mL−1, respectively. Next, a cylindrical NdFeB magnet 
(dimensions: diameter = 12 mm, height = 10 mm: field strength, 0.5 T) was placed under the 
glass-bottomed dish for 24 h. Cells were then washed three times with PBS, medium exchanged for 
fresh reduced serum medium (opti-MEM) and cells were observed by confocal laser scanning 
microscopy (CLSM; LSM510META, Carl Zeiss, Oberkochen, Germany). CLSM observations were 
performed with excitation by an argon laser (488 nm for Alexa488) or He-Ne laser (543 nm for 
rhodamine B). Emitted fluorescence was detected through a 503–530 nm band pass filter and a 
543-nm-long pass filter. The magnetic field was applied to cells and MCs in a glass-bottomed dish or a 
12-well plate using a Nd-B-Fe magnet, as shown in Figure S3c. To obtain a uniform magnetic 
environment for each cell, a sufficiently large magnet (length, 100 mm; width, 100 mm; height, 10 mm) 
was used to fully cover the glass-bottomed dish or 12-well plate.  
 
Flow cytometry. HeLa cells were seeded on a 12-well plate at a density of 1.0×105 cells per well and 
incubated overnight. After the medium was exchanged for fresh DMEM, MC/protein suspension was 
added to each well. The final concentrations of MC, insulin, and BSA were 10, 1.4 and 1.7 µg mL−1, 
respectively. Next, a cylindrical NdFeB magnet (dimensions: diameter = 12 mm, height = 10 mm: field 
strength, 0.5 T) was placed under the glass bottom dish for 24 h. Cells were then washed three times 
with PBS, trypsinized and suspended in staining buffer (BD PharMingen, New Jersey, USA). Flow 
cytometry was performed with a Cytomix FC500 (Beckman Coulter, California, USA) with a 488 nm 
He-Ne laser. Signals from the FL1 band pass emission were used for FITC or Alexa488.  
 
Protein release from MC in the presence of FBS. MC/protein complex (MC, 100 µg mL−1; insulin, 
1.4 µg mL−1; BSA, 1.7 µg mL−1) was incubated with serum proteins (PBS, 10% FBS, or 20% FBS in 
PBS) for 24 h. At each timepoint, MC/protein complex was separated from released proteins under a 
magnetic field (0.5 T) and the complexation ratio (%), as a relative amount of released protein to total 
protein, was calculated by measuring the fluorescence intensity of FITC or Alexa488 in the released 
protein fraction. In addition, encapsulation of serum proteins contained in FBS was confirmed by 
polyacrylamide gel electrophoresis. The gel was stained by Coomassie brilliant blue (CBB) and 
detected by an LAS luminescence imaging system (LAS 4000 mini, Fujifilm, Tokyo, Japan). 
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Enzymatic activity of β-galactosidase. The enzymatic activity of β-galactosidase was evaluated using 
Tokyo-green β-gal as a substrate. Non-fluorescent Tokyo-green β-gal is converted to fluorescent 
Tokyo-green by a hydrolytic reaction catalyzed by β-galactosidase. The fluorescence of Tokyo-green 
was measured in a fluorescence spectrometer (excitation at 490 nm, emission at 510 nm). The 
MC/β-galactosidase complex (MC, 100 µg mL−1; β-galactosidase, 0.42 µg mL−1) was maintained at 
37 °C and its incorporated β-galactosidase was separated from free β-galactosidase under a magnetic 
field. Tokyo-green β-gal (10 nM) was added to the separated complex at 1 min. After 5 min incubation, 
serum proteins (20% FBS) were added to the solution. The enzymatic activity of β-galactosidase was 
estimated from the slope of the Tokyo-green signal intensity change within 15 min. The relative 
enzymatic activity of β-galactosidase was calculated by comparing values to the enzymatic activity of 
free β-galactosidase (0.42 µg mL−1). 
 
Intracellular delivery of β-galactosidase. HeLa cells were seeded on a multi-well plate at a density of 
1.0×105 cells/well and incubated overnight. After the culture medium was removed and exchanged for 
fresh DMEM, the MC/β-galactosidase complex (MC, 10 µg mL−1; β-galactosidase, 0.042 µg mL−1) was 
added to each well with or without applying a magnetic field. After incubation for 24 h, cells were 
washed three times with PBS and Tokyo green-β-gal solution (10 µM) was added to the treated cells. 
After an additional 3 h, cells were washed three times with PBS, their medium was exchanged for fresh 
opti-MEM, and they were observed by CLSM. For flow cytometry, cells were trypsinized after 
Tokyo-green β-gal treatment and re-suspended in staining buffer. Flow cytometry was performed with a 
Cytomix FC500 (Beckman Coulter) with a 488 nm He-Ne laser. The signals from the FL1 band pass 
emission were used for Tokyo-green. 
 
Prodrug assay with 5-fluorouridine-5′-O-β-galactopyranoside. HeLa cells were seeded on a 96-well 
plate (BD Falcon) at a density of 5.0×103 cells/well and incubated overnight. After the medium was 
exchanged for fresh DMEM, MC/β-galactosidase complex (MC, 10 µg mL−1; β-galactosidase, 0.047 µg 
mL−1) was added to each well with or without applying a magnetic field. After incubation for 24 h, cells 
were washed three times with PBS and 5-FUR-β-gal (100 µM) was applied to each well. After further 
incubation for 24 h, a Cell Counting Kit-8 reagent (10 µL) was added to each well and plates were 
incubated for 2 h. The absorbance at 450 nm was then measured with a plate reader. The cell viability 
was calculated relative to that of untreated cells. 
 
Delivery of caspase 3. CT26; murine colon cancer cells were seeded on a 96-well plate at a density of 
5.0×103 cells/well. After overnight incubation, the cell culture medium was replaced and MC/caspase 3 
complex was added to the cells at various concentrations of caspase 3 with or without a magnetic field. 
The concentration of MC was fixed at 100 µg mL−1. After 24 h incubation, cell viability was quantified 
with a Cell Counting Kit-8 by measuring absorbance at 450 nm using a microplate reader.  
 
Apoptosis detection assay. CT26; murine colon cancer cells were seeded on a 96-well plate at a 
density of 5.0×103 cells/well. After overnight incubation, the cell culture medium was replaced and a 
MC/caspase 3 complex was added to the cells at various concentrations of caspase 3 with or without a 
magnetic field. The concentration of MC was fixed at 100 µg mL−1. After 24 h of incubation, cells were 
trypsinized and re-suspended in a working mixture containing Ca2+ ions. After FITC-labeled annexin-V 
and propidium iodide (PI) were added to the suspension, the cells were analyzed using flow cytometry 
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2. Basic characterization of MCs 
 
 
Figure S1. Histogram of the number of iron oxide nanoparticles in a nanogel 
(a) MC1, (b) MC10, and (c) MC100. These histograms were obtained by counting the number of iron 
oxide nanoparticles from TEM images of MCs. Fifty individual MCs were counted. 
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3. Size and Zeta-potential of MC and MC/protein complexes 
 
 
Table S2. Hydrodynamic diameters and ζ-potentials of MC and MC/protein complexes in PBS. The 
particle size of MC and MC encapsulating proteins were determined by dynamic light scattering in PBS. 
The zeta-potentials were determined using capillary cells. PDI is the polydispersity index. The results 
































Sample RH (nm) PDI ζ-potential (mV) 
MC1 110 ± 0 0.10 ± 0.01 −1.0 ± 0.6 
MC1/insulin complex 160 ± 13 0.26 ± 0.01  0.7 ± 1.8 
MC1/BSA complex 180 ± 10 0.25 ± 0.02 −0.5 ± 0.4 
MC1/β-galactosidase complex 180 ± 20 0.25 ± 0.00 −0.3 ± 1.3 
MC10 140 ± 20 0.06 ± 0.02 −0.0 ± 0.0 
MC10/insulin complex 170 ± 20 0.24 ± 0.01  1.3 ± 0.3 
MC10/BSA complex 160 ± 10 0.24 ± 0.01 −0.6 ± 1.0 
MC10/β-galactosidase complex 190 ± 20 0.25 ± 0.01  0.9 ± 1.3 
MC100 180 ± 0 0.04 ± 0.01 −0.5 ± 1.4 
MC100/insulin complex 180 ± 10 0.25 ± 0.01  0.0 ± 0.1 
MC100/BSA complex 170 ± 20 0.23 ± 0.01 −1.3 ± 0.5 
MC100/β-galactosidase complex 180 ± 10 0.24 ± 0.01 −0.4 ± 2.2 
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Figure S2. Interactions between nanogel/Alexa488-labeled BSA complexes and Hela cells (a) or 
MC1/Alexa488-labeled BSA complexes without a magnetic field (b) or MC1/Alexa488-labeled BSA 
complexes with a magnetic field (c). The concentrations of nanogel and BSA were 100 and 17 µg mL−1, 
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5. Magnetic field dependency of magnetically guided delivery using MCs 
 
Figure S3. (a) Dependence of intracellular delivery efficiency on magnetic field intensities of 
MC/protein complex toward HeLa cells. Hela cells were seeded on 12-well plates (1.0×105 cells/well), 
and MC was added to cells (100 µg mL−1) under the influence of various strengths of magnetic field. To 
produce various magnetic field strengths toward cells, the distance between cells and the magnet were 
varied between 1 and 100 mm. Intracellular uptake was then quantified by flow cytometry. (b) 
Intracellular uptake efficiencies were compared by applying magnetic fields in different orientations. 
The magnet was placed on the top, side or bottom of the dish. HeLa cells were seeded on 12-well plates 
(1.0×105 cells/well), and MC was added to cells (100 µg mL−1) under the influence of a magnetic field. 
The intracellular uptake was quantified by flow cytometry. (c) Schematic representing the direction of 
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6. Endocytosis inhibition 
 
 
Figure S4. Intracellular uptake inhibition experiment. HeLa cells were seeded on 12-well plates 
(1.0×105 cells/well, and three independent experiments were performed in triplicate). The seeded cells 
were treated with MC under a magnetic field at 4°C or 37°C for 24 h. Cells were trypsinized and 
redispersed in staining buffer. The cellular uptake efficiencies of MC were quantified by flow cytometry. 
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7. Protein exchange reaction 
 
 
Figure S5. Complexation of serum proteins in FBS with MC via an exchange reaction evaluated by 
SDS-PAGE. The MC/BSA complex (MC, 100 µg mL−1; BSA, 17 µg mL−1) interacted with 10% FBS. 
The MC/BSA complex, which were magnetically separated from FBS, were treated with sodium 
dodecyl sulfate with heating at 70°C. The electrophoresis was carried out using a 7.5% polyacrylamide 
gel (20 mA, 70 min). The gel was stained with Coomassie brilliant blue (CBB). Lanes 1 and 2 indicate 
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8. Insulin delivery with MC 
 
Figure S6. (a) Complex formation with FITC-labeled insulin. MC (100 µg mL−1) and FITC-insulin (14 
µg mL−1) were mixed in PBS. The complexation ratio (%), the relative amount of free protein to total 
protein, was quantified by measuring the fluorescence intensity from the free insulin isolated from the 
complex by magnetic separation. Three independent experiments were performed in triplicate. (b) Cell 
internalization of MC/FITC-insulin complexes. CLSM images of HeLa cells after 24 h incubation with 
rhodamine B (red)-labeled MC/FITC-labeled insulin (green) in the absence of a magnetic field. The 
scale bar indicates 20 µm. (c) The mean fluorescence of rhodamine-labeled MC and FITC-labeled 
insulin accumulated in HeLa cells was measured by flow cytometry after 24 h incubation of cells with 
MC−1/FITC-insulin complexes. Three independent experiments were performed in triplicate. (d) 
Protein release in the presence of a highly concentrated protein solution, mimicking the intracellular 
environment using serum proteins. After complexation with insulin, PBS (●) or FBS (10%◆, 20%▲) 
was added to the complex and the ratio of incorporated insulin was calculated by measuring 
fluorescence intensity of the free insulin isolated from the complex by magnetic separation. Three 
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9. Protein transduction  
 
 
Figure S7. Confocal laser scanning microscopic (CLSM) image of HeLa cells incubated without 
treatment (a), with free β-galactosidase (b), nanogel (CHP)/β-galactosidase complex (c), cationic 
nanogel (CHP-NH2)/β-galactosidase complex (d) MC/β-galactosidase complex without a magnetic field 
or MC/β-galactosidase complex with a magnetic field for 24 hr. Tokyo-green-β-gal (10 µM) was added 
to HeLa cells before CLSM observation. The concentrations of CHP, CHP-NH2 and MC were fixed at 
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10. Enzymatic activity of delivered protein within cells 
 
 
Figure S8. Enzymatic activity of β-galactosidase within cells. HeLa cells were treated with a 
MC1/β-galactosidase complex (MC1, 10 µg mL−1; β-galactosidase, 0.042 µg mL−1). After 
administration of this complex, Tokyo green β-gal (10 µM) was also added to the cells. Tokyo-green 
fluorescence was monitored for the first 20 min, after incubation for 0 h (circles), after 24 h (triangles) 





Table S3. Relative enzymatic activity of β-galactosidase delivered to HeLa cells with a 
MC1/β-galactosidase complex (MC1, 10 µg mL−1; β-galactosidase, 0.042 µg mL−1). After 
administration of this complex, Tokyo green β-gal (10 µM) was also added to cells. The relative 
enzymatic activity was quantified by the slope of the change in intensity of Tokyo-green fluorescence, 
measured over 20 min, after the indicated incubation times. 
 
 

















This article is protected by copyright. All rights reserved 
160419SI





Figure S9. Cytotoxicity of 5-fluorouridine (5-FUR, open circles) and 5-fluorouridine 
-O-β-galactopyranoside (5-FUR-β-gal, closed circles) toward HeLa cells when incubated for 24 h. 
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12. Apoptosis detection assay 
 
 
Figure S10. Apoptosis detection assay; annexin-V/PI staining. The stages of apoptosis were identified 
by Annexin-V/PI staining. Non-treated CT26 cells (a). CT26 cells treated with a MC/caspase-3 complex 
(50 nM, b; 100 nM, c) with or without a magnetic field (100 nM, d) for 24 h.  
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